A federal appeals court panel that heard oral arguments in the PCSK9 inhibitor patent dispute June 6 focused its attention on evidentiary rulings and the validity of Amgen Inc.’s patents but did not raise any questions about a lower court order blocking US sales of Sanofi and Regeneron Pharmaceuticals Inc.’s Praluent (alirocumab).
Sanofi and Regeneron may have made some headway in their arguments to the Federal Circuit US Court of Appeals that a lower judge erred in excluding evidence the Praluent partners say was critical to invalidating Amgen’s patents
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?